Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone732-524-0400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$81.58 billion
Profitability
Miscellaneous
Employees135,100
Next Earnings Date10/15/2019 (Estimated)
OptionableOptionable
Johnson & Johnson (NYSE:JNJ) Frequently Asked Questions
What is Johnson & Johnson's stock symbol?
Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."
How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?
Johnson & Johnson declared a quarterly dividend on Monday, July 15th. Investors of record on Tuesday, August 27th will be given a dividend of $0.95 per share on Tuesday, September 10th. This represents a $3.80 annualized dividend and a yield of 2.91%. The ex-dividend date is Monday, August 26th. View Johnson & Johnson's Dividend History.
How will Johnson & Johnson's stock buyback program work?
Johnson & Johnson declared that its board has authorized a stock buyback program on Monday, December 17th 2018, which authorizes the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 1.5% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's board of directors believes its stock is undervalued.
How were Johnson & Johnson's earnings last quarter?
Johnson & Johnson (NYSE:JNJ) issued its quarterly earnings results on Tuesday, July, 16th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $2.42 by $0.16. The business had revenue of $20.56 billion for the quarter, compared to the consensus estimate of $20.39 billion. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The firm's revenue was down 1.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.10 EPS. View Johnson & Johnson's Earnings History.
When is Johnson & Johnson's next earnings date?
How can I listen to Johnson & Johnson's earnings call?
Johnson & Johnson will be holding an earnings conference call on Tuesday, October 15th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.
What guidance has Johnson & Johnson issued on next quarter's earnings?
Johnson & Johnson updated its FY19 earnings guidance on Tuesday, July, 16th. The company provided EPS guidance of $8.53-8.63 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.62. The company issued revenue guidance of $80.8-81.6 billion, compared to the consensus revenue estimate of $81.27 billion.
What price target have analysts set for JNJ?
11 equities research analysts have issued 1 year price targets for Johnson & Johnson's stock. Their predictions range from $140.00 to $157.00. On average, they expect Johnson & Johnson's share price to reach $149.75 in the next year. This suggests a possible upside of 14.7% from the stock's current price. View Analyst Price Targets for Johnson & Johnson.
What is the consensus analysts' recommendation for Johnson & Johnson?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Johnson & Johnson.
Has Johnson & Johnson been receiving favorable news coverage?
Media coverage about JNJ stock has trended positive recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Johnson & Johnson earned a coverage optimism score of 2.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the next several days. View News Stories for Johnson & Johnson.
Are investors shorting Johnson & Johnson?
Johnson & Johnson saw a increase in short interest in July. As of July 31st, there was short interest totalling 15,811,200 shares, an increase of 7.4% from the June 30th total of 14,719,000 shares. Based on an average trading volume of 7,390,000 shares, the days-to-cover ratio is presently 2.1 days. Approximately 0.6% of the shares of the stock are sold short. View Johnson & Johnson's Current Options Chain.
Who are some of Johnson & Johnson's key competitors?
Some companies that are related to Johnson & Johnson include Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Pfizer (PFE), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Sanofi (SNY), Eli Lilly And Co (LLY), GlaxoSmithKline (GSK), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG) and Zoetis (ZTS).
What other stocks do shareholders of Johnson & Johnson own?
Who are Johnson & Johnson's key executives?
Johnson & Johnson's management team includes the folowing people:
- Mr. Alex Gorsky, Chairman & CEO (Age 59)
- Mr. Joseph J. Wolk CPA, Exec. VP & CFO (Age 52)
- Dr. Paulus A. Stoffels, Chief Scientific Officer (Age 57)
- Mr. Michael H. Ullmann, Exec. VP & Gen. Counsel (Age 60)
- Mr. Joaquin Duato, Vice Chairman of Exec. Committee (Age 56)
Who are Johnson & Johnson's major shareholders?
Johnson & Johnson's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.53%), BlackRock Inc. (7.12%), Phocas Financial Corp. (4.74%), Phocas Financial Corp. (4.74%), Northern Trust Corp (1.34%) and Bank of New York Mellon Corp (1.20%). Company insiders that own Johnson & Johnson stock include Alex Gorsky, Charles Prince, Joaquin Duato, Marillyn A Hewson, Michael E Sneed, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta. View Institutional Ownership Trends for Johnson & Johnson.
Which institutional investors are selling Johnson & Johnson stock?
JNJ stock was sold by a variety of institutional investors in the last quarter, including Barrow Hanley Mewhinney & Strauss LLC, Barrow Hanley Mewhinney & Strauss LLC, UBS Asset Management Americas Inc., BlackRock Inc., Independent Franchise Partners LLP, Swedbank, Quest Capital Management Inc. ADV and Investec Asset Management LTD. Company insiders that have sold Johnson & Johnson company stock in the last year include Alex Gorsky, Joaquin Duato, Michael E Sneed, Peter Fasolo and Ronald A Kapusta. View Insider Buying and Selling for Johnson & Johnson.
Which institutional investors are buying Johnson & Johnson stock?
JNJ stock was acquired by a variety of institutional investors in the last quarter, including Phocas Financial Corp., Phocas Financial Corp., Nuveen Asset Management LLC, Thoroughbred Financial Services LLC, Renaissance Technologies LLC, Price T Rowe Associates Inc. MD, APG Asset Management N.V. and Vanguard Group Inc.. Company insiders that have bought Johnson & Johnson stock in the last two years include Charles Prince and Marillyn A Hewson. View Insider Buying and Selling for Johnson & Johnson.
How do I buy shares of Johnson & Johnson?
Shares of JNJ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Johnson & Johnson's stock price today?
One share of JNJ stock can currently be purchased for approximately $130.60.
How big of a company is Johnson & Johnson?
Johnson & Johnson has a market capitalization of $344.68 billion and generates $81.58 billion in revenue each year. The company earns $15.30 billion in net income (profit) each year or $8.18 on an earnings per share basis. Johnson & Johnson employs 135,100 workers across the globe.View Additional Information About Johnson & Johnson.
What is Johnson & Johnson's official website?
How can I contact Johnson & Johnson?
Johnson & Johnson's mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company can be reached via phone at 732-524-0400.
MarketBeat Community Rating for Johnson & Johnson (NYSE JNJ)
MarketBeat's community ratings are surveys of what our community members think about Johnson & Johnson and other stocks. Vote "Outperform" if you believe JNJ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNJ will underperform the S&P 500 over the long term. You may vote once every thirty days.
